UBS Group Cuts Moderna (NASDAQ:MRNA) Price Target to $96.00

Moderna (NASDAQ:MRNA) had its price target decreased by UBS Group from $108.00 to $96.00 in a research note issued to investors on Wednesday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

MRNA has been the subject of several other reports. Leerink Partners reduced their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. TD Cowen reduced their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Bank of America reaffirmed an “underperform” rating and issued a $41.00 price objective on shares of Moderna in a research report on Tuesday, December 10th. Berenberg Bank assumed coverage on Moderna in a report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price objective for the company. Finally, Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $78.83.

Moderna Price Performance

MRNA opened at $42.25 on Wednesday. The firm has a 50-day moving average of $42.52 and a 200 day moving average of $69.84. Moderna has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The firm has a market cap of $16.26 billion, a P/E ratio of -7.26 and a beta of 1.60. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.39) earnings per share. On average, research analysts expect that Moderna will post -9.3 EPS for the current year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last ninety days. 15.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Douglas Lane & Associates LLC raised its position in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after acquiring an additional 298,715 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Moderna by 31.9% in the fourth quarter. GAMMA Investing LLC now owns 3,173 shares of the company’s stock valued at $132,000 after acquiring an additional 768 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Moderna by 4.2% in the third quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after buying an additional 15,218 shares during the last quarter. Inspire Trust Co. N.A. grew its position in shares of Moderna by 73.5% during the 3rd quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company’s stock valued at $1,104,000 after acquiring an additional 7,000 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its stake in shares of Moderna by 1.4% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company’s stock worth $19,239,000 after buying an additional 3,978 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.